When faced with telemedicine caseloads much lower than those in the early coronavirus disease 2019 (COVID-19) pandemic, practitioners of neuromuscular medicine might be tempted to think of digital health as a passing trend of the early 2020s. However, the use of digital, Internetconnected devices for monitoring patient outcomes has seen sustained growth over the past few years and continues to flourish. Digital health, or "computing platforms, connectivity, software, and sensors for health care and related uses," 1 encompasses a broadly expressed set of tools through which patients receive care. Its potential in neurology has been proposed to be two-fold: (1) to supplement existing practices in ways that are objective, valid, and less burdensome for patients; and (2) as a complete re-imagination of the neurologic exam, its players, and the environment in which it is conducted. 1 Synchronous telemedicine consultation represents just one such implementation of digital health. Digital biomarkers, developed at the intersection of medicine, materials science, and engineering, are another rapidly expanding field in this landscape. Digital biomarkers use a sensor to collect objective data on a biological, anatomical, or physiological parameter, often paired with algorithms that process these data into meaningful outcome measures. 2 These devices can